The Medicare agency will extend a short-term program that will pay for weight-loss drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, guaranteeing access to the popular medications will continue for seniors next year. The decision by the Centers for Medicare and Medicaid Services comes after big Medicare insurers signaled that they didn’t initially plan to join a separate, longer-term payment model for the drugs that was supposed to launch at the start of 2027, throwing its future into question. Instead, the interim Medicare program, which starts in July and was expected to run only until the end of 2026, will continue until the end of 2027.
Read the full article: Medicare Delays Full Obesity-Drug Program Rollout After Insurers Push Back //
Source: https://www.wsj.com/health/pharma/medicare-delays-full-obesity-drug-program-rollout-after-insurers-push-back-d1c3d73d